Gemin X Pharmaceuticals is dedicated to the discovery, development and commercialization of novel, targeted cancer therapeutics to improve the lives of patients.
Gemin X's research on the Bcl-2 cell death regulation pathway has led to the discovery of GX15-070 (obatoclax), a novel small molecule that selectively reinitiates programmed cell death, or apoptosis, and may also be effective in inducing cancer cell self-digestion, or autophagy. Obatoclax has shown promising activity in both preclinical and early human clinical studies and is currently in Phase 2 clinical trials as both a single agent and combination therapy. Obatoclax has patent protection through 2025.
Current Team (4)Update
Funding Rounds (4) - $71.3MUpdate
Oldest investment firms
Caxton Advantage Life Science Fund is a New York-based financial firm that invests into companies...
Ontario Teachers' Pension Plan invests and administers the pensions of active and retired...
SB Life Science Equity Management is a venture capital firm that is dedicated to funding and...
HBM Partners is among the global leaders in Life Science-focused investing with approximately USD...
Labor Sponsored Devpt Fund
Pinnacle Ventures is a private venture capital fund focused on providing debt and equity...
A Financial Institution
3576 Avenue du Parc
Suite 4310, QC
Montréal, H2X 2H7